SCHEMBL6319396

SCHEMBL6319396

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4ccc(F)cc4F)c32)c(C)c1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.67
KDR P35968 9/20 0.53
FLT3 P36888 6/20 0.53
FLT4 P35916 4/20 0.53
KIT P10721 2/20 0.53
PRKAA2 P54646 4/20 0.51
PRKAA1 Q13131 4/20 0.51
PDGFRB P09619 5/20 0.51
EGFR P00533 1/20 0.51
PDGFRA P16234 1/20 0.51
AURKB Q96GD4 3/20 0.50
HDAC3 O15379 3/20 0.49
HDAC4 P56524 3/20 0.49
HDAC1 Q13547 3/20 0.49
HDAC7 Q8WUI4 3/20 0.49
HDAC2 Q92769 3/20 0.49
HDAC10 Q969S8 3/20 0.49
HDAC11 Q96DB2 3/20 0.49
HDAC8 Q9BY41 3/20 0.49
HDAC6 Q9UBN7 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321852 0.90 ALK (0.60) ALKKDRFLT3FLT4KIT
SCHEMBL6320428 0.90 ALK (0.60) ALKKDRFLT3FLT4KIT
SCHEMBL6321440 0.88 ALK (0.66) ALKKDRFLT3FLT4KIT
SCHEMBL6321447 0.88 ALK (0.66) ALKKDRFLT3FLT4KIT
SCHEMBL6322055 0.87 ALK (0.59) ALKKDRFLT3FLT4KIT
SCHEMBL6321006 0.87 ALK (0.65) ALKKDRFLT3FLT4KIT
SCHEMBL6321012 0.87 ALK (0.65) ALKKDRFLT3FLT4KIT
SCHEMBL6323699 0.87 ALK (0.61) ALKKDRFLT3FLT4KIT
SCHEMBL6324399 0.87 ALK (0.64) ALKKDRFLT3FLT4KIT
SCHEMBL6321574 0.85 KDR (0.58) ALKKDRFLT3KITPRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ALK 1015/4885KDR 819/4885FLT3 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.